DIANA technology can be advantegously used not only for effective kinase inhibitor profiling, but any DIANA assay available in our profiling portfolio can be readily transformed into the powerful high-throughput screening (HTS) assay. In this setup, screened compounds compete with the DIANA probe for the target binding. It offers sensitive hit discovery (ultra-low false-positive and false-negative rate) while providing direct quantification of the compound’s inhibition potency (Kd). It also allows highly efficient screening of pooled libraries leading to a reduced screening cost and time.
This makes it suitable not only for large pharma high-throughput-screening facilities but also for smaller-scale projects at academic institutions (in-house libraries of ~10k compounds can be screened in just several 384-well plates). Finally, we can also offer a characterization of ADME properties of identified lead compounds that can emerge from the HTS campaigns.
Download the complete HTS Leaflet
Document name | Download |
|---|---|
Pick the library and send us your requirements
Our High-Throughput Screening (HTS) services provide access to diverse fragment-based libraries, which include low molecular weight and structurally varied molecules critical for identifying promising drug leads. We offer two main compound sets: the Lead-like Diversity Set and the Drug-like Diversity Set. Additionally, we provide focused libraries tailored for targeted screening, such as the Kinase Inhibitor Library and the FDA-approved Drug Library.
Clients can utilize our HTS services with any assay available in our inhibitor profiling portfolio or request a custom-designed assay tailored to their specific target and research objectives. Project timelines and pricing are highly dependent on the scope and requirements and are discussed and agreed upon individually.
This compound collection is designed to facilitate the discovery of novel active scaffolds. Hits from these libraries typically have low binding affinity (Kd > 1 µM), making them excellent starting points for further optimization and structure-activity relationship (SAR) studies.
Containing appx. 10,000 compounds (over 6,000 scaffolds)
Compounds with low MW (MW<400 Da) and logP (0-3)
No PAINS, only medchem friendly compounds
Drug Discovery Services
We can seamlessly convert any DIANA assay from our inhibitor profiling portfolio into a high-throughput screening (HTS) format. If your target is not currently covered in our DIANA assay portfolio, we can also custom-develop a DIANA assay tailored specifically to your needs. HTS utilizing DIANA technology offers sensitive hit discovery with a direct potency (Kd) readout and demonstrates exceptional robustness and reproducibility. This is evidenced by our typical Z' factors exceeding 0.7 in HTS campaigns. Moreover, our methodology supports efficient pooled library screening, which significantly reduces screening costs and time. This service is suitable for both pharmaceutical and academic projects, offering high sensitivity, reliability, and scalability for diverse research goals.
Our assays deliver robust and reproducible results across a wide range of targets, including those considered challenging. This reliability helps minimize project setbacks and ensures greater confidence in your screening outcomes.
We can establish and deliver high-throughput screening (HTS) services within 3 months. This accelerated setup significantly shortens early discovery timelines and allows you to quickly move from assay design to actionable results.
DIANA assays can be developed as stand-alone services tailored to your specific project needs, or seamlessly integrated into broader collaborative programs. This flexibility makes them suitable for both large pharma pipelines and smaller academic initiatives.
To support your project goals, we provide models with defined performance milestones and risk-sharing options. This ensures transparency, reduces upfront risk, and aligns our success directly with your discovery outcomes.
